TSMC reported Q2 2026 net income of T$706.56 billion (about US$21.98 billion), a record that beat analyst estimates of T$632.6 billion and jumped roughly 77% from the same quarter a year earlier (CNBC, Reuters). Profit rose over 23% from the prior quarter. Net revenue reached NT$1,270.38 billion, up 12.0% from Q1 (TSMC Management Report). The earnings call took place on July 13, 2026.

TSMC also set a Q3 2026 revenue floor of $44.6 billion (CNBC). Alongside the results, the company pledged an additional $100 billion in U.S. investment (Reuters). The commitment comes amid pressure on chip supply chains to move advanced manufacturing onto U.S. soil.

The size of the earnings beat — T$74 billion above what analysts expected — tells its own story. When a foundry of TSMC's scale posts a double-digit sequential revenue increase on top of a 77% year-on-year profit surge, the main driver is pricing power at the most advanced manufacturing nodes, not just higher volumes. (A "foundry" makes chips designed by other companies; "leading-edge nodes" are the smallest, most efficient transistor sizes available.) The Q3 revenue floor of $44.6 billion, if reached, would continue the acceleration from Q1's US$35.90 billion in revenue, which was itself up 40.6% year-over-year (TSMC press release). January–February 2026 revenue had already totaled NT$718.91 billion, up 29.9% from the same period in 2025 (TSMC press release).

Chip Stocks Sell Off Despite the Print

The record results did not lift the sector. On July 16, 2026, the PHLX Semiconductor Index (SOX) fell 5%, and the Nasdaq Composite slipped about 1% (WSJ). Sandisk, Western Digital, and Marvell were among the biggest Nasdaq losers that session. The selloff was global: chip stocks declined across markets from Asia to the U.S., with AI-related names falling broadly (Reuters).

The weakness extended a pattern from the prior session. On July 15, 2026, Micron Technology shares declined 8%, Lam Research dropped 3%, and AMD also fell (CNBC). That sell-down happened even as SK Hynix shares surged nearly 13% the same day, driven by AI optimism and tracking U.S. stock gains (Reuters). South Korean chip equipment maker Hanmi gained about 25% in early trade that session.

The divergence — a foundry reporting record profit while the semiconductor complex sells off — points to positioning and expectations rather than fundamentals. The AI trade narrative has cycled through multiple phases in recent weeks. The Wall Street Journal described it in a May 31 article as powering stocks to a "historic rally" (WSJ). By July 7, the Journal reported a "U.S. Stocks Retreat on Worries About AI Trade," citing a sharp selloff in chip stocks (WSJ). Two days later, on July 9, investors revived the trade, sparking a tech rally (WSJ). SK Hynix's U.S. ADR debut on July 10, priced at $149 and opening 14% higher, was characterized by the Journal as the AI trade passing "another test" (Reuters, WSJ). Yet by July 13, another selloff materialized (WSJ).

The broader context here is that this pattern has become familiar enough for markets to price in. When consensus estimates are beaten by T$74 billion and the sector still sells off 5%, the question shifts from earnings performance to whether investors are rethinking how long the AI spending cycle can last. The $100 billion U.S. investment pledge, layered on top of existing commitments, raises the capital intensity of the entire AI infrastructure build-out — and with it, the break-even utilization rates that foundries and their suppliers need to sustain. TSMC's Q3 guidance floor of $44.6 billion in revenue is the number to watch: any sequential slowdown from there would narrow the gap between elevated spending and revenue growth, and markets are clearly already wrestling with that risk.

UnitedHealth Group Raises 2026 Guidance

UnitedHealth Group reported Q2 2026 revenues of $112.0 billion, earnings from operations of $8.0 billion, and earnings of $6.04 per share, raising its full-year 2026 guidance alongside the results (UnitedHealth Group). The release was issued before the market open on July 16. UNH traded at $423.88 at midday.

UnitedHealth's results offer a counterweight to the tech-driven narrative. A $112 billion quarterly revenue base with an operating margin of roughly 7.1% and a raised full-year outlook is a fundamentally different earnings profile from the semiconductor cycle. The healthcare conglomerate's ability to lift guidance — in a period when tech investors are de-risking the AI trade — reflects a divergence in earnings visibility across sectors that is worth noting, though any causal link between the two would be speculative.